Albemarle Total Cost of Revenue decreased by 24.6% to $927.77M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $920.58M to $927.77M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 17.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $525.48M | $581.29M | $657.61M | $678.70M | $899.17M | $1.05B | $1.62B | $1.30B | $1.81B | $2.26B | $3.06B | $1.32B | $1.44B | $1.46B | $1.09B | $920.58M | $1.13B | $1.19B | $1.23B | $927.77M |
| QoQ Change | — | +10.6% | +13.1% | +3.2% | +32.5% | +16.6% | +54.5% | -19.5% | +39.0% | +24.5% | +35.7% | -56.8% | +9.0% | +1.2% | -25.0% | -15.8% | +23.1% | +5.0% | +3.4% | -24.6% |
| YoY Change | — | — | — | — | +71.1% | +80.3% | +146.3% | +92.1% | +101.5% | +115.2% | +88.9% | +1.4% | -20.5% | -35.3% | -64.3% | -30.4% | -21.4% | -18.4% | +12.5% | +0.8% |